Hector Tamez Aguilar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Dialysis | 14 | 2013 | 1796 | 1.360 |
Why?
|
Ergocalciferols | 4 | 2013 | 110 | 1.230 |
Why?
|
Vitamin D Deficiency | 5 | 2013 | 1388 | 0.990 |
Why?
|
Vitamin D | 8 | 2013 | 3303 | 0.950 |
Why?
|
Hypertrophy, Left Ventricular | 4 | 2013 | 851 | 0.890 |
Why?
|
Cardiac Volume | 2 | 2013 | 197 | 0.800 |
Why?
|
Vitamins | 4 | 2013 | 1635 | 0.680 |
Why?
|
Kidney Failure, Chronic | 7 | 2013 | 2472 | 0.680 |
Why?
|
Erythropoietin | 2 | 2013 | 719 | 0.570 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2013 | 2242 | 0.550 |
Why?
|
Heart Atria | 2 | 2013 | 1345 | 0.550 |
Why?
|
Drug Resistance | 2 | 2013 | 1596 | 0.510 |
Why?
|
Bone Density Conservation Agents | 2 | 2013 | 795 | 0.500 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 131 | 0.410 |
Why?
|
Carbamates | 1 | 2013 | 191 | 0.390 |
Why?
|
Parathyroid Hormone | 3 | 2013 | 1803 | 0.380 |
Why?
|
Serum Albumin | 2 | 2013 | 672 | 0.370 |
Why?
|
Hematinics | 1 | 2013 | 282 | 0.360 |
Why?
|
Receptors, Erythropoietin | 1 | 2010 | 144 | 0.340 |
Why?
|
Bone Diseases, Metabolic | 1 | 2013 | 409 | 0.330 |
Why?
|
Gelsolin | 1 | 2009 | 189 | 0.310 |
Why?
|
Glucuronidase | 1 | 2009 | 202 | 0.300 |
Why?
|
Twins | 1 | 2009 | 339 | 0.290 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2009 | 353 | 0.270 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1974 | 0.250 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2012 | 1723 | 0.230 |
Why?
|
Pregnancy Trimester, Second | 1 | 2007 | 731 | 0.230 |
Why?
|
Anemia | 1 | 2013 | 1509 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 558 | 0.220 |
Why?
|
Dietary Supplements | 2 | 2013 | 3415 | 0.220 |
Why?
|
Pregnancy Trimester, First | 1 | 2007 | 907 | 0.210 |
Why?
|
Hypertension | 2 | 2013 | 8540 | 0.200 |
Why?
|
Actins | 1 | 2009 | 2050 | 0.190 |
Why?
|
Kidney Diseases | 1 | 2012 | 2091 | 0.180 |
Why?
|
Communicable Diseases | 1 | 2009 | 875 | 0.180 |
Why?
|
Hyperparathyroidism, Secondary | 2 | 2012 | 125 | 0.160 |
Why?
|
Diabetes, Gestational | 1 | 2009 | 1248 | 0.160 |
Why?
|
Ventricular Function, Left | 1 | 2012 | 3879 | 0.160 |
Why?
|
Blood Pressure | 2 | 2013 | 8481 | 0.150 |
Why?
|
Receptors, Cell Surface | 1 | 2007 | 2822 | 0.150 |
Why?
|
Pre-Eclampsia | 1 | 2007 | 1231 | 0.150 |
Why?
|
Risk Factors | 10 | 2013 | 74213 | 0.140 |
Why?
|
Angiogenesis Inhibitors | 1 | 2007 | 2048 | 0.140 |
Why?
|
Phosphorus | 2 | 2008 | 335 | 0.140 |
Why?
|
Antigens, CD | 1 | 2007 | 4001 | 0.140 |
Why?
|
Peptide Fragments | 1 | 2008 | 5112 | 0.130 |
Why?
|
Death, Sudden, Cardiac | 2 | 2013 | 1555 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2009 | 6484 | 0.110 |
Why?
|
Case-Control Studies | 7 | 2013 | 22176 | 0.110 |
Why?
|
Multivariate Analysis | 4 | 2013 | 12059 | 0.110 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2013 | 1390 | 0.110 |
Why?
|
Biological Availability | 1 | 2013 | 390 | 0.110 |
Why?
|
Aged | 14 | 2013 | 169310 | 0.090 |
Why?
|
Cardiovascular Diseases | 2 | 2013 | 15502 | 0.090 |
Why?
|
Proteinuria | 1 | 2013 | 607 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15936 | 0.090 |
Why?
|
Female | 18 | 2013 | 392705 | 0.080 |
Why?
|
STAT5 Transcription Factor | 1 | 2010 | 265 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2012 | 423 | 0.080 |
Why?
|
Male | 17 | 2013 | 360846 | 0.080 |
Why?
|
Cathelicidins | 1 | 2009 | 80 | 0.080 |
Why?
|
Logistic Models | 3 | 2013 | 13255 | 0.080 |
Why?
|
Homozygote | 1 | 2013 | 1776 | 0.080 |
Why?
|
Humans | 24 | 2013 | 761596 | 0.080 |
Why?
|
Odds Ratio | 4 | 2013 | 9647 | 0.080 |
Why?
|
Prospective Studies | 8 | 2013 | 54423 | 0.080 |
Why?
|
Renin-Angiotensin System | 1 | 2013 | 737 | 0.080 |
Why?
|
K562 Cells | 1 | 2010 | 642 | 0.080 |
Why?
|
Pregnancy, Multiple | 1 | 2009 | 215 | 0.080 |
Why?
|
Middle Aged | 12 | 2013 | 220921 | 0.080 |
Why?
|
Double-Blind Method | 2 | 2012 | 12341 | 0.070 |
Why?
|
Molecular Weight | 1 | 2010 | 2186 | 0.070 |
Why?
|
Hemoglobins | 1 | 2013 | 1526 | 0.070 |
Why?
|
Genotype | 2 | 2013 | 12990 | 0.070 |
Why?
|
Hyperparathyroidism | 1 | 2007 | 337 | 0.060 |
Why?
|
Survival Analysis | 2 | 2009 | 10090 | 0.060 |
Why?
|
Fatty Acids | 1 | 2013 | 1808 | 0.060 |
Why?
|
United States | 6 | 2013 | 72340 | 0.060 |
Why?
|
Linkage Disequilibrium | 1 | 2009 | 1998 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4021 | 0.060 |
Why?
|
Sodium, Dietary | 1 | 2007 | 425 | 0.060 |
Why?
|
Cohort Studies | 5 | 2013 | 41495 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2013 | 58984 | 0.060 |
Why?
|
Health Surveys | 1 | 2013 | 4061 | 0.050 |
Why?
|
Arrhythmias, Cardiac | 1 | 2013 | 2244 | 0.050 |
Why?
|
Glomerular Filtration Rate | 1 | 2012 | 2178 | 0.050 |
Why?
|
Linear Models | 1 | 2013 | 5872 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 4243 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2013 | 64685 | 0.050 |
Why?
|
Gene Frequency | 1 | 2009 | 3606 | 0.050 |
Why?
|
Fibroblast Growth Factors | 1 | 2008 | 867 | 0.050 |
Why?
|
Blotting, Western | 1 | 2010 | 5035 | 0.050 |
Why?
|
Echocardiography | 2 | 2012 | 4989 | 0.050 |
Why?
|
Reference Values | 1 | 2009 | 4920 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2008 | 15266 | 0.050 |
Why?
|
Animals | 5 | 2013 | 168475 | 0.040 |
Why?
|
Bone Density | 1 | 2013 | 3551 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2010 | 3208 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2013 | 26129 | 0.040 |
Why?
|
Phosphorylation | 1 | 2010 | 8321 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 4352 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2371 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2009 | 2922 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8527 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10766 | 0.040 |
Why?
|
Chronic Disease | 1 | 2012 | 9319 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2008 | 12463 | 0.030 |
Why?
|
Time Factors | 3 | 2013 | 39969 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 8002 | 0.030 |
Why?
|
Pregnancy | 2 | 2009 | 29890 | 0.030 |
Why?
|
Massachusetts | 1 | 2009 | 8833 | 0.030 |
Why?
|
Cell Line | 1 | 2010 | 15601 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2009 | 12794 | 0.030 |
Why?
|
Calcium | 1 | 2007 | 5722 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18399 | 0.020 |
Why?
|
Arachidonic Acid | 1 | 2013 | 427 | 0.020 |
Why?
|
Incidence | 1 | 2009 | 21355 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2013 | 540 | 0.020 |
Why?
|
Adult | 3 | 2009 | 221210 | 0.020 |
Why?
|
Eicosapentaenoic Acid | 1 | 2013 | 561 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2009 | 26202 | 0.020 |
Why?
|
Rats, Inbred Dahl | 1 | 2007 | 34 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2013 | 1039 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2008 | 39106 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3415 | 0.020 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 1516 | 0.020 |
Why?
|
Atrial Natriuretic Factor | 1 | 2007 | 350 | 0.020 |
Why?
|
Algorithms | 1 | 2007 | 14033 | 0.020 |
Why?
|
Docosahexaenoic Acids | 1 | 2013 | 907 | 0.020 |
Why?
|
Phosphates | 1 | 2008 | 770 | 0.010 |
Why?
|
Organ Size | 1 | 2007 | 2254 | 0.010 |
Why?
|
Young Adult | 1 | 2009 | 59260 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10212 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 6180 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 9420 | 0.010 |
Why?
|
Rats | 1 | 2007 | 23741 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 11904 | 0.010 |
Why?
|